SCHEMBL17400591

SCHEMBL17400591

CC(=O)Nc1nc(-c2cc(Cl)cc(C(F)(F)F)c2)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.62
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
ALDH1A1 P00352 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALOX5 P09917 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GSTO1 P78417 1/20 0.48
DYRK1A Q13627 1/20 0.48
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
TYR P14679 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18723983 0.86 ABL1 (0.53) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL17386703 0.86 ABL1 (0.55) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL18724406 0.85 ABL1 (0.51) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL17400663 0.83 ALDH1A1 (0.64) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL21301111 0.83 NPC1 (0.56) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL19133707 0.82 ABL1 (0.59) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL18724400 0.81 ABL1 (0.69) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL17412735 0.81 ABL1 (0.62) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL6984546 0.79 ABL1 (0.69) ABL1RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL19448226 0.78 DYRK1A (0.46) ABL1ALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49111-E1 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2022-06-21 US disclosed
EP-2963036-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF ASTELLAS PHARMA INC (JP) 2019-08-28 EP disclosed
EP-3153511-B1 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES ASTELLAS PHARMA INC (JP) 2019-05-15 EP disclosed
US-9951060-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2018-04-24 US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 US disclosed
US-9844549-B2 2-aminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-12-19 US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 US disclosed
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-10-12 US disclosed
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2017-07-13 US disclosed
EP-3153511-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2017-04-12 EP disclosed
US-9562044-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2017-02-07 US disclosed
EP-2963036-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF Astellas Pharma Inc. (JP) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197955-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 ABL1 3850/4885RAB9A 2439/4885NPC1 4139/4885
US-20170290824-A1 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF CHRM3, CHRM2, TRPM2 ABL1 2969/4885RAB9A 2245/4885NPC1 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.